BR112022015888A2 - Receptores de células t restritos a hla classe i contra ras com mutação g12d - Google Patents
Receptores de células t restritos a hla classe i contra ras com mutação g12dInfo
- Publication number
- BR112022015888A2 BR112022015888A2 BR112022015888A BR112022015888A BR112022015888A2 BR 112022015888 A2 BR112022015888 A2 BR 112022015888A2 BR 112022015888 A BR112022015888 A BR 112022015888A BR 112022015888 A BR112022015888 A BR 112022015888A BR 112022015888 A2 BR112022015888 A2 BR 112022015888A2
- Authority
- BR
- Brazil
- Prior art keywords
- mutation
- restricted
- cell receptors
- hla class
- receptors against
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 5
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 5
- 102000016914 ras Proteins Human genes 0.000 title abstract 3
- 230000035772 mutation Effects 0.000 title abstract 2
- 102200006539 rs121913529 Human genes 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 235000003704 aspartic acid Nutrition 0.000 abstract 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 150000002333 glycines Chemical group 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000003259 recombinant expression Methods 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464464—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/00041—Use of virus, viral particle or viral elements as a vector
- C12N2740/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Developmental Biology & Embryology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
Abstract
RECEPTORES DE CÉLULAS T RESTRITOS A HLA CLASSE I CONTRA RAS COM MUTAÇÃO G12D. A presente invenção refere-se a um receptor de células T isolado ou purificado (TCR), em que o TCR tem especificidade antigênica para uma sequência de aminoácido de RAS humano mutado com uma substituição de glicina na posição 12 por ácido aspártico apresentado por uma molécula de classe I de antígeno leucocitário humano (HLA). Também são fornecidos polipeptídeos e proteínas relacionados, bem como ácidos nucleicos relacionados, vetores de expressão recombinantes, células hospedeiras, populações de células e composições farmacêuticas. Também são divulgados métodos de detecção da presença de câncer em um mamífero e métodos de tratamento ou prevenção de câncer em um mamífero.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062975544P | 2020-02-12 | 2020-02-12 | |
| PCT/US2021/017794 WO2021163434A1 (en) | 2020-02-12 | 2021-02-12 | Hla class i-restricted t cell receptors against ras with g12d mutation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022015888A2 true BR112022015888A2 (pt) | 2022-10-11 |
Family
ID=74860472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022015888A BR112022015888A2 (pt) | 2020-02-12 | 2021-02-12 | Receptores de células t restritos a hla classe i contra ras com mutação g12d |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230080742A1 (pt) |
| EP (1) | EP4103597A1 (pt) |
| JP (1) | JP2023528112A (pt) |
| KR (1) | KR20220143867A (pt) |
| CN (1) | CN115279784A (pt) |
| AU (1) | AU2021221138A1 (pt) |
| BR (1) | BR112022015888A2 (pt) |
| CA (1) | CA3168015A1 (pt) |
| CL (1) | CL2022002208A1 (pt) |
| CO (1) | CO2022012922A2 (pt) |
| CU (1) | CU20220044A7 (pt) |
| GB (1) | GB2609760A (pt) |
| IL (1) | IL295252A (pt) |
| MX (1) | MX2022009654A (pt) |
| TW (1) | TW202140536A (pt) |
| WO (1) | WO2021163434A1 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021351710A1 (en) * | 2020-10-02 | 2023-06-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class ii-restricted dq t cell receptors against ras with g13d mutation |
| WO2022183167A1 (en) | 2021-02-25 | 2022-09-01 | Alaunos Therapeutics, Inc. | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| WO2023150562A1 (en) | 2022-02-01 | 2023-08-10 | Alaunos Therapeutics, Inc. | Methods for activation and expansion of t cells |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004021995A2 (en) | 2002-09-06 | 2004-03-18 | The Government Of The United States Of America, Represented By The Secretary, Departement Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| JP6863893B2 (ja) * | 2014-11-26 | 2021-04-21 | アメリカ合衆国 | 抗突然変異ｋｒａｓ ｔ細胞受容体 |
| CN108395479B (zh) * | 2017-02-06 | 2021-07-16 | 高军 | 一种有关kras基因突变的t细胞受体 |
| CA3084246A1 (en) * | 2017-12-04 | 2019-06-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class i-restricted t cell receptors against mutated ras |
-
2021
- 2021-02-12 CA CA3168015A patent/CA3168015A1/en active Pending
- 2021-02-12 GB GB2211733.7A patent/GB2609760A/en active Pending
- 2021-02-12 KR KR1020227031175A patent/KR20220143867A/ko unknown
- 2021-02-12 AU AU2021221138A patent/AU2021221138A1/en active Pending
- 2021-02-12 US US17/799,163 patent/US20230080742A1/en active Pending
- 2021-02-12 MX MX2022009654A patent/MX2022009654A/es unknown
- 2021-02-12 IL IL295252A patent/IL295252A/en unknown
- 2021-02-12 WO PCT/US2021/017794 patent/WO2021163434A1/en unknown
- 2021-02-12 CU CU2022000044A patent/CU20220044A7/es unknown
- 2021-02-12 JP JP2022548811A patent/JP2023528112A/ja active Pending
- 2021-02-12 EP EP21710730.9A patent/EP4103597A1/en active Pending
- 2021-02-12 BR BR112022015888A patent/BR112022015888A2/pt unknown
- 2021-02-12 TW TW110105194A patent/TW202140536A/zh unknown
- 2021-02-12 CN CN202180014038.2A patent/CN115279784A/zh active Pending
-
2022
- 2022-08-12 CL CL2022002208A patent/CL2022002208A1/es unknown
- 2022-09-12 CO CONC2022/0012922A patent/CO2022012922A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN115279784A (zh) | 2022-11-01 |
| WO2021163434A1 (en) | 2021-08-19 |
| IL295252A (en) | 2022-10-01 |
| CA3168015A1 (en) | 2021-08-19 |
| WO2021163434A8 (en) | 2022-09-01 |
| US20230080742A1 (en) | 2023-03-16 |
| GB202211733D0 (en) | 2022-09-28 |
| MX2022009654A (es) | 2022-10-20 |
| EP4103597A1 (en) | 2022-12-21 |
| GB2609760A (en) | 2023-02-15 |
| JP2023528112A (ja) | 2023-07-04 |
| CL2022002208A1 (es) | 2023-06-02 |
| CU20220044A7 (es) | 2023-06-13 |
| KR20220143867A (ko) | 2022-10-25 |
| TW202140536A (zh) | 2021-11-01 |
| CO2022012922A2 (es) | 2022-10-21 |
| AU2021221138A1 (en) | 2022-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022015888A2 (pt) | Receptores de células t restritos a hla classe i contra ras com mutação g12d | |
| MX2020005765A (es) | Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado. | |
| BR112022015897A2 (pt) | Receptores de célula t restritos à classe i de hla contra ras com mutação de g12v | |
| BR112022016661A2 (pt) | Receptores de células t restritos ao hla classe ii contra ras com mutação g12v | |
| BR112021026408A2 (pt) | Receptores de célula t que reconhecem a mutação r175h ou y220c em p53 | |
| JP2021178854A (ja) | がんの処置および予防のためのワクチン | |
| MX2019009641A (es) | Receptores de la celula t que reconocen mhc de mage-a3 de clase ii-restringida. | |
| EP3301107B1 (en) | Novel peptides that bind to types of mhc class ii and their use in diagnosis and treatment | |
| Makarkov et al. | Plant-derived virus-like particle vaccines drive cross-presentation of influenza A hemagglutinin peptides by human monocyte-derived macrophages | |
| BR112022001923A2 (pt) | Proteína de ligação ao antígeno, ácido nucleico isolado, célula hospedeira recombinante, composição farmacêutica, método de produção da proteína de ligação ao antígeno | |
| BR112021005702A2 (pt) | método para selecionar neoepítopos | |
| Liu et al. | Major histocompatibility complex: Interaction with peptides | |
| Infantes et al. | Natural HLA-B* 2705 protein ligands with glutamine as anchor motif: implications for HLA-B27 association with spondyloarthropathy | |
| Schmid et al. | MHC class II antigen loading compartments continuously receive input from autophagosomes | |
| BR112013013158B1 (pt) | composições farmacêutica para uso no tratamento de câncer, métodos in vitro para induzir célula apresentadora de antígeno, bem como vetor, e uso | |
| Duvvuri et al. | The human immune system recognizes neopeptides derived from mitochondrial DNA deletions | |
| Van Schravendijk et al. | Comparative structural analysis of HLA-A3 antigens distinguishable by cytotoxic T lymphocytes: variant E1. | |
| WO2021262829A3 (en) | Hla class i-restricted t cell receptors against cd20 | |
| Mádi et al. | Altered sialylation on the cell-surface proteins of dexamethasone-treated human macrophages contributes to augmented uptake of apoptotic neutrophils | |
| BR112023021806A2 (pt) | Métodos e composições compreendendo peptídeos mhc classe i | |
| Kim et al. | Differential signatures of protein glycosylation and phosphorylation in human Chang liver cells induced by TCDD treatment | |
| Vielhaben et al. | Predicting the binding of SARS-CoV-2 peptides to the major histocompatibility complex with recurrent neural networks | |
| Maryanski et al. | Structural features of peptides recognized by H-2Kd-restricted T cells | |
| Poljački et al. | MHC class II antigens in alopecia areata | |
| WO2024023521A1 (en) | Tolerogenic peptides |